View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
October 1, 2012

Janssen executes agreement to develop JAK inhibitor for immunological diseases

Janssen Biotech has executed a licensing contract with Astellas Pharma for the worldwide development and commercialisation of an oral, small molecule Janus Kinase (JAK) inhibitor, ASP015K, except in Japan.

Janssen Biotech has executed a licensing contract with Astellas Pharma for the worldwide development and commercialisation of an oral, small molecule Janus Kinase (JAK) inhibitor, ASP015K, except in Japan.

ASP015K is at present in Phase IIb studies evaluating the efficacy and safety of once-daily oral dosing, in the treatment of moderate-to-severe rheumatoid arthritis.

A Phase IIa study in the treatment of moderate-to-severe plaque psoriasis has been completed.

ASP105K blocks critical components of signalling mechanisms used by a number of inflammatory cytokines.

Janssen research and development immunology global therapeutic area head Dr Susan Dillon said; "We are committed to expanding the portfolio of new treatments for patients with serious immune-mediated diseases and are excited to add Astellas’ ASP015K to our pipeline."

According to the agreement, Janssen receives exclusive worldwide rights to develop and commercialise ASP015K as an oral treatment for immune-mediated inflammatory diseases, except in Japan. Astellas will continue developing ASP015K in Japan.

Janssen will make an upfront payment as well as future milestone and royalty payments upon the achievement of certain development and commercialisation milestones.

Pursuant to the contract, Astellas is responsible for completing the ongoing Phase IIb studies while Janssen is responsible for all other development, clinical and regulatory filing activities in its territories.

Rheumatoid arthritis results in pain and inflammation, and in some cases, joint destruction and disability.

Psoriasis is a chronic inflammatory disease that results from the overproduction of skin cells.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena